Furthermore, a team used the PPARγ agonist rosiglitazone (RGZ) to treat esophageal cancer cells and discovered that application of RGZ could suppress cellular proliferation and induce apoptosis, while PPARγ inhibition could partially restore the RGZ-treated effect, suggesting that activation of PPARγ with specific agonists could inhibit cancer cell growth and cancer progression (Wu et al., 2016). This evidence concerns the gene PPARG and esophageal cancer.